Spine: A Non-vertebral: not demonstrated Hip: not demonstrated
In a randomised trial of 7,705 postmenopausal osteoporotic women receiving calcium and vitamin D, 3 years treatment with raloxifene 60mg daily improved the risk of vertebral fracture (rr 0.7). Treatment groups also experienced an improvement in the spine and femur of 2-3%.
The risk of oestrogen receptor positive breast cancer after 40 months follow up was significantly reduced (rr 0.24). There was no increase inthe risk of vaginal bleeding or endometrial cancer. Raloxifene has favourable effects on cardiovascular markers but its effects on coronary artery disease have not been established.
Raloxifene increases the frequency of hot flushes, leg cramps and peripheral oedema and also increases the risk of venous thromboembolism.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.